Atlas Trials

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

Clinical trial NCT05491083 · RECRUITING

Trial details

NCT number
NCT05491083
Sponsor
National University Hospital, Singapore
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Advanced Solid TumorTriple Negative Breast Cancer
Start date
2023-06-12
Primary completion
2026-12-31
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.